Patents Assigned to VistaGen Therapeutics, Inc.
  • THERAPEUTIC USES OF L-4-CHLOROKYNURENINE
    Publication number: 20240122887
    Abstract: Pharmaceutical compositions comprising L-4-chlorokynurenine and associated therapeutic methods are provided for the treatment of certain neurological and other conditions.
    Type: Application
    Filed: September 30, 2022
    Publication date: April 18, 2024
    Applicant: VISTAGEN THERAPEUTICS, INC.
    Inventor: H. Ralph SNODGRASS
  • Synthesis of 4-chlorokynurenines and intermediates
    Patent number: 11427530
    Abstract: The invention relates to an overall enantio-specific synthesis of 4-chlorokynurenine compounds, in particular L-4-chlorokynurenine, with improved yields. Large-scale syntheses are disclosed. The invention also relates to novel intermediates in the synthesis of L-4-chlorokynurenine.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: August 30, 2022
    Assignee: VISTAGEN THERAPEUTICS, INC.
    Inventors: Daniel Levin, Peter Leeming, Emerich Eisenreich, Xuejun Karl Liu
  • Dosage forms and therapeutic uses of L-4-chlorokynurenine
    Patent number: 10980758
    Abstract: Compositions of L-4-chlorokynurenic are provided, as are methods for the treatment of neurological dysfunction.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: April 20, 2021
    Assignee: VISTAGEN THERAPEUTICS, INC.
    Inventors: H. Ralph Snodgrass, Allen E. Cato, Jack S. Hicklin
  • Dosage forms and therapeutic uses of L-4-chlorokynurenine
    Patent number: 10821089
    Abstract: Compositions of L-4-chlorokynurenic are provided, as are methods for the treatment of neurological dysfunction.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: November 3, 2020
    Assignee: VISTAGEN THERAPEUTICS, INC.
    Inventors: H. Ralph Snodgrass, Allen E. Cato, Jack S. Hicklin
  • Dosage forms and therapeutic uses of L-4-chlorokynurenine
    Patent number: 10632091
    Abstract: Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurologica dyslinction.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: April 28, 2020
    Assignee: VISTAGEN THERAPEUTICS, INC.
    Inventors: H. Ralph Snodgrass, Allen E. Cato, Jack S. Hicklin
  • Dosage forms and therapeutic uses of L-4-chlorokynurenine
    Patent number: 10617663
    Abstract: Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: April 14, 2020
    Assignee: VISTAGEN THERAPEUTICS, INC.
    Inventors: H. Ralph Snodgrass, Allen E. Cato, Jack S. Hicklin
  • THERAPEUTIC USES OF L-4-CHLOROKYNURENINE
    Publication number: 20190321317
    Abstract: Pharmaceutical compositions comprising L-4-chlorokynurenine and associated therapeutic methods are provided for the treatment of certain neurological and other conditions.
    Type: Application
    Filed: May 6, 2019
    Publication date: October 24, 2019
    Applicant: VISTAGEN THERAPEUTICS, INC.
    Inventor: H. Ralph SNODGRASS
  • Methods for the synthesis of chiral kynurenine compounds
    Patent number: 10294502
    Abstract: Provided are methods for synthesizing compounds, including chiral kynurenine compounds. The methods are suitable for large-scale manufacture and produce the chiral kynurenines compounds in high chemical purity and high chiral purity.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: May 21, 2019
    Assignee: VISTAGEN THERAPEUTICS, INC.
    Inventors: Stefan Abele, Klaus Laue, Roland A. Breitenmoser
  • DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE
    Publication number: 20190125707
    Abstract: Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurologica dyslinction.
    Type: Application
    Filed: May 14, 2018
    Publication date: May 2, 2019
    Applicant: VISTAGEN THERAPEUTICS, INC.
    Inventors: H. Ralph SNODGRASS, Allen E. CATO, Jack S. HICKLIN
  • METHODS FOR THE SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS
    Publication number: 20180171372
    Abstract: Provided are methods for synthesizing compounds, including chiral kynurenine compounds. The methods are suitable for large-scale manufacture and produce the chiral kynurenines compounds in high chemical purity and high chiral purity.
    Type: Application
    Filed: November 14, 2017
    Publication date: June 21, 2018
    Applicant: VISTAGEN THERAPEUTICS, INC.
    Inventors: Stefan ABELE, Klaus LAUE, Roland A. BREITENMOSER
  • Dosage forms and therapeutic uses L-4-chlorokynurenine
    Patent number: 9993453
    Abstract: Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: June 12, 2018
    Assignee: VISTAGEN THERAPEUTICS, INC.
    Inventors: H. Ralph Snodgrass, Allen E. Cato, Jack S. Hicklin
  • Dosage forms and therapeutic uses of L-4-chlorokynurenine
    Patent number: 9993450
    Abstract: Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: June 12, 2018
    Assignee: VISTAGEN THERAPEUTICS, INC.
    Inventors: H. Ralph Snodgrass, Allen E. Cato, Jack S. Hicklin
  • Methods for the synthesis of chiral kynurenine compounds
    Patent number: 9834801
    Abstract: Provided are methods for synthesizing compounds, including chiral kynurenine compounds. The methods are suitable for large-scale manufacture and produce the chiral kynurenines compounds in high chemical purity and high chiral purity.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 5, 2017
    Assignee: VISTAGEN THERAPEUTICS, INC.
    Inventors: Stefan Abele, Klaus Laue, Roland A. Breitenmoser
  • DOSAGE FORMS AND THERAPEUTIC USES L-4-CHLOROKYNURENINE
    Publication number: 20160158178
    Abstract: Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction.
    Type: Application
    Filed: February 8, 2016
    Publication date: June 9, 2016
    Applicant: VISTAGEN THERAPEUTICS, INC.
    Inventors: H. Ralph SNODGRASS, Allen E. CATO, Jack S. HICKLIN
  • Toxicity typing using liver stem cells
    Patent number: 8512957
    Abstract: This invention provides methods and systems for identifying and typing toxicity of chemical compositions, as well as for screening new compositions for toxicity. The invention involves detecting alterations in gene or protein expression and hence establishing molecular profiles in isolated mammalian LSCs contacted with various chemical compositions of known and unknown toxicities, and correlating the molecular profiles with toxicities of the chemical compositions.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: August 20, 2013
    Assignee: Vistagen Therapeutics, Inc.
    Inventor: H. Ralph Snodgrass
  • TOXICITY TYPING USING LIVER STEM CELLS
    Publication number: 20120220469
    Abstract: This invention provides methods and systems for identifying and typing toxicity of chemical compositions, as well as for screening new compositions for toxicity. The invention involves detecting alterations in gene or protein expression and hence establishing molecular profiles in isolated mammalian LSCs contacted with various chemical compositions of known and unknown toxicities, and correlating the molecular profiles with toxicities of the chemical compositions.
    Type: Application
    Filed: February 21, 2012
    Publication date: August 30, 2012
    Applicant: VistaGen Therapeutics, Inc.
    Inventor: H. Ralph SNODGRASS